Helsinn Group, presented data at the International Society of Paediatric Oncology (SIOP) congress establishing that palonosetron, at a dose 20 mug/kg, is a valuable and efficacious treatment option for chemotherapy-induced nausea and vomiting (CINV) in pediatric patients up to 17 years of age. CINV is a common and distressing side-effect of chemotherapy which, if inadequately controlled, can lead to dehydration, electrolyte imbalance and hospitalization.

The data (presented at the SIOP congress in Toronto, 22-24 October, today, October 23rd) derive from a large randomized trial and establish that the investigated higher dose palonosetron (20 mug/kg), given as a single dose, demonstrated similar efficacy to multiple daily administrations of ondansetron up to 32mg/day (considered current standard of care) in the prevention of CINV in pediatric patients receiving highly emetogenic chemotherapy.

READ FULL ARTICLE Curated publisher From Medical News Today